Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Danesi R et al. | Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. | 2003 | J. Antimicrob. Chemother. | pmid:12654753 |
| Muñoz B et al. | Antibiotic dosage in trachoma control programs: height as a surrogate for weight in children. | 2003 | Invest. Ophthalmol. Vis. Sci. | pmid:12657580 |
| Gibb AM et al. | Should we offer antibiotic prophylaxis post sexual assault? | 2003 | Int J STD AIDS | pmid:12662387 |
| Ito N and Kudo S | [Case of polycystic lung disease with mixed infections due to Aspergillus and Mycobacterium fortuitum successfully treated by AZM]. | 2002 | Jpn J Antibiot | pmid:12664928 |
| Hunter RP et al. | Azithromycin metabolite identification in plasma, bile, and tissues of the ball python (Python regius). | 2003 | J. Vet. Pharmacol. Ther. | pmid:12667181 |
| Gerhardt SG et al. | Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. | 2003 | Am. J. Respir. Crit. Care Med. | pmid:12672648 |
| Schilling F | [SAPHO syndrome. A contribution to discussion]. | 2003 | Wien. Klin. Wochenschr. | pmid:12674695 |
| Corbu C et al. | [Ocular toxoplasmosis and consecutive complicated cataract]. | 2002 | Oftalmologia | pmid:12677800 |
| Zhou WQ et al. | [Clinic efficacy of treating chronic prostatitis caused by Neisseria gonorrhoeae with azithromycin aspartic-acid injection]. | 2003 | Zhonghua Nan Ke Xue | pmid:12680331 |
| Sicklinger M et al. | In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto. | 2003 | J. Clin. Microbiol. | pmid:12682190 |
| Karlowsky JA et al. | Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). | 2003 | Clin. Infect. Dis. | pmid:12684907 |
| Hamdan II | Comparative in vitro investigations of the interaction between some macrolides and Cu(II), Zn(II) and Fe(II). | 2003 | Pharmazie | pmid:12685822 |
| Schachter J and Dawson CR | Elimination of blinding trachoma. | 2002 | Curr. Opin. Infect. Dis. | pmid:12686881 |
| Krudsood S et al. | A comparative clinical trial of combinations of dihydroartemisinin plus azithromycin and dihydroartemisinin plus mefloquine for treatment of multidrug resistant falciparum malaria. | 2002 | Southeast Asian J. Trop. Med. Public Health | pmid:12693587 |
| Malcolm C and Marrie TJ | Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting. | 2003 | Arch. Intern. Med. | pmid:12695270 |
| Seral C et al. | Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. | 2003 | J. Antimicrob. Chemother. | pmid:12697643 |
| Faa AG et al. | Scrub typhus in the Torres Strait islands of north Queensland, Australia. | 2003 | Emerging Infect. Dis. | pmid:12702230 |
| Cascio A and Colomba C | [Macrolides in the treatment of children with Mediterranean spotted fever]. | 2002 | Infez Med | pmid:12704264 |
| Strle F and Maraspin V | Is azithromycin treatment associated with prolongation of the Q-Tc interval? | 2002 | Wien. Klin. Wochenschr. | pmid:12708094 |
| Jacks SS et al. | In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials. | 2003 | Antimicrob. Agents Chemother. | pmid:12709351 |
| Hoban DJ et al. | Comparative in vitro surveillance of amoxicillin-clavulanic acid and four oral comparators against 21232 clinical isolates from europe. | 2003 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:12709842 |
| Faber M et al. | [Comparative analysis of the effectiveness and costs of azithromycin and cefoperazone treatment of patients during COPD exacerbation]. | 2003 | Pol. Merkur. Lekarski | pmid:12712826 |
| Basualdo W and Arbo A | Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. | 2003 | Pediatr. Infect. Dis. J. | pmid:12712971 |
| Fernández-Cuenca F et al. | In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin or imipenem against clinical isolates of Acinobacter baumannii. | 2003 | Chemotherapy | pmid:12714805 |
| Prata A et al. | Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. | 2003 Jan-Feb | Rev. Soc. Bras. Med. Trop. | pmid:12715065 |
| Bird M et al. | Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas? | 2003 | J. Infect. Dis. | pmid:12721948 |
| Yoshida H and Kusaba N | [Cat scratch disease]. | 2003 | Nippon Rinsho | pmid:12722263 |
| Guchev IA et al. | [Prophylaxis of pneumonia occurring outside the hospital in organized groups]. | 2003 | Voen Med Zh | pmid:12722363 |
| Guchev IA et al. | [Effect of chemoprophylaxis on pneumonia incidence in organized groups]. | 2003 | Voen Med Zh | pmid:12722514 |
| Maekawa M et al. | [Alteration of antibacterial activity of tosufloxacin and various antibacterial agents against Streptococcus pneumoniae]. | 2003 | Jpn J Antibiot | pmid:12723396 |
| Johnson SR et al. | Mutations causing in vitro resistance to azithromycin in Neisseria gonorrhoeae. | 2003 | Int. J. Antimicrob. Agents | pmid:12727073 |
| Skerk V et al. | Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. | 2003 | Int. J. Antimicrob. Agents | pmid:12727080 |
| Trad O et al. | Eradication of Cryptosporidium in four children with acute lymphoblastic leukemia. | 2003 | J. Trop. Pediatr. | pmid:12729299 |
| Llor Vilà C | [I'd rather give azithromycin for three days. That way the patient complies]. | 2003 | Aten Primaria | pmid:12735886 |
| Gaynor BD et al. | Eliminating trachoma in areas with limited disease. | 2003 | Emerging Infect. Dis. | pmid:12737745 |
| Chanteux H et al. | Cell handling, membrane-binding properties, and membrane-penetration modeling approaches of pivampicillin and phthalimidomethylampicillin, two basic esters of ampicillin, in comparison with chloroquine and azithromycin. | 2003 | Pharm. Res. | pmid:12739771 |
| Bachmann K et al. | Influence of a 3-day regimen of azithromycin on the disposition kinetics of cyclosporine A in stable renal transplant patients. | 2003 | Pharmacol. Res. | pmid:12742010 |
| Sánchez F et al. | Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia? | 2003 | Clin. Infect. Dis. | pmid:12746768 |
| Castaldo RS et al. | A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. | 2003 | Clin Ther | pmid:12749513 |
| Frick KD et al. | Household willingness to pay for azithromycin treatment for trachoma control in the United Republic of Tanzania. | 2003 | Bull. World Health Organ. | pmid:12751418 |
| Karlowsky JA et al. | Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. | 2003 | Antimicrob. Agents Chemother. | pmid:12760850 |
| Yamaguchi H et al. | Chlamydia pneumoniae resists antibiotics in lymphocytes. | 2003 | Antimicrob. Agents Chemother. | pmid:12760877 |
| Zhanel GG et al. | Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. | 2003 | J. Antimicrob. Chemother. | pmid:12775677 |
| Blandford JM and Gift TL | The cost-effectiveness of single-dose azithromycin for treatment of incubating syphilis. | 2003 | Sex Transm Dis | pmid:12782951 |
| Jang D et al. | Correlation between culture testing of swabs and ligase chain reaction of first void urine from patients recently treated for Chlamydia trachomatis. | 2003 | Sex Transm Infect | pmid:12794211 |
| Andrews WW et al. | Randomized clinical trial of extended spectrum antibiotic prophylaxis with coverage for Ureaplasma urealyticum to reduce post-cesarean delivery endometritis. | 2003 | Obstet Gynecol | pmid:12798523 |
| Engel JN | Azithromycin-induced block of elementary body formation in Chlamydia trachomatis. | 1992 | Antimicrob. Agents Chemother. | pmid:1280057 |
| Iakovlev SV and Ukhin SA | [Azithromycin: general properties and regimen optimization based on pharmacokinetic and pharmacological parameters]. | 2003 | Antibiot. Khimioter. | pmid:12803047 |
| Peters DH et al. | Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. | 1992 | Drugs | pmid:1280567 |
| Ito K et al. | Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. | 2003 | Drug Metab. Dispos. | pmid:12814973 |